Fig. 4: PGE2 facilitates Mtb survival within lung MSCs in vivo.

a Total bacterial CFU in the lungs of C57BL/6 mice infected with H37Rv via aerosol route (~10² bacilli/lung) administered with vehicle, celecoxib (50 mg/kg), INH (10 mg/kg), or combination of celecoxib with INH (50 mg/kg and 10 mg/kg, respectively). Treatments started 4 weeks post infection and were given every day for next 8 weeks. b Total bacterial CFU from the spleen of infected animals during the course of experiment mentioned above (c) Gating strategy for sorting of MSCs and monocyte/macrophages from mice lung. Live singlet population was gated for CD45 positive and negative population which were sub-gated based on Ly6G⁻CD11b⁺ for macrophages or myeloid cells and Sca1⁺CD73⁺ for MSCs, respectively. d Characterization of the gated macrophage and MSC population with additional cell specific surface marker. Upper panel is for CD11b⁺ macrophage stained for Ly6G, CD11c, Ly6C, and MHCII. Lower panel is for CD73⁺ MSCs stained with CD11b, CD44, CD90, and CD105. e–f Change in lung tissue landscape comprising macrophages (CD45⁺Ly6G⁻CD11b⁺) and MSCs across 12 weeks of infection and upon treatment with celecoxib, INH or celecoxib + INH. g–h Mtb survival within sorted macrophages (CD45⁺Ly6G⁻CD11b⁺) and MSCs (CD45⁻Sca1⁺CD73⁺) along the course of infection and treatment as discussed above. All above data are represented as mean ± SD, n = 3 independent experiments (total ten mice). Statistical analysis was done Mann−Whitney U test. Source data are included in the source data file.